Glenmark Pharmaceuticals S.r.o. Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: Glenmark Pharmaceuticals S.r.o. Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Glenmark Pharmaceuticals S.r.o. — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Glenmark Pharmaceuticals S.r.o.

Pharmaceutical Importer · Germany · Antimalarial & Antiparasitic Focus · $1.1M Total Trade · DGFT Verified

Glenmark Pharmaceuticals S.r.o. is a pharmaceutical importer based in Germany with a total trade value of $1.1M across 2 products in 2 therapeutic categories. Based on 33 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Glenmark Pharmaceuticals S.r.o. sources from 7 verified Indian suppliers, with Glenmark Pharmaceuticals Limited accounting for 94.0% of imports.

Glenmark Pharmaceuticals S.r.o. — Import Portfolio & Supplier Network

Glenmark Pharmaceuticals S.r.o. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Glenmark Pharmaceuticals S.r.o.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Glenmark Pharmaceuticals Limited	$38.0M	1,661	94.0%
Macleods Pharmaceuticals Limited	$794.8K	49	2.0%
Unison Pharmaceuticals Private Limited

What Formulations Does Glenmark Pharmaceuticals S.r.o. Import?

Formulation	Value	Ships
Ryaltris 240 md fr (sfr020007b060401hc)	$1.3M	25
Trospipharm ge 20MG TAB 30s majorelle	$728.3K	18
Atova/prog tabs 250/100MG 2000's bulk	$600.0K	12
Atova sus 750MG/5ML 250ML fr- biogaran	$450.0K	9
Ryaltris 240 md pl (spl220007b060401hc)	$300.0K	6
Ryaltris 240 md es (ses050007b060401hc)	$300.0K	6
Tranylcypromine 10MG fc tabs 28s	$250.0K	5
Atova/prog tabs 250/100MG 2000's	$250.0K	5
Telmisartan tabs 40MG bulk 4000#s	$234.4K	6
Adisocol tabs 150MG 60s	$222.1K	5
Ryaltris 240 md	$218.1K	5
Mometasone furoate oint 30GM nl	$208.3K	12
Clabilla 20 MG tabletki(3x10t)bl	$207.5K	6
Ryaltris 240 md dk/no	$200.0K	4
Ryaltris 240 md fi/se	$200.0K	4

Glenmark Pharmaceuticals S.r.o. imports 1,217 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atovaquone	Antimalarial & Antiparasitic	$750.0K	15	0.1%	5
2	Efavirenz	Antivirals	$390.3K	18	0.6%	15

Glenmark Pharmaceuticals S.r.o. imports 2 pharmaceutical products across 2 categories into Germany totaling $1.1M.

Glenmark Pharmaceuticals S.r.o. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Glenmark Pharmaceuticals S.r.o. is a pharmaceutical importer and buyer based in Germany, specializing in the acquisition of finished pharmaceutical formulations from India. As a subsidiary of Glenmark Pharmaceuticals Limited, an Indian multinational company headquartered in Mumbai, Glenmark Pharmaceuticals S.r.o. plays a pivotal role in distributing Glenmark's products within the German market. Glenmark Pharmaceuticals Limited, established in 1977, has a global presence with operations in over 80 countries, focusing on therapeutic areas such as respiratory, dermatology, and oncology.

In Germany, Glenmark Pharmaceuticals S.r.o. functions as a key player in the pharmaceutical supply chain, facilitating the import and distribution of Glenmark's pharmaceutical products. The company's operations are integral to ensuring the availability of Glenmark's medications in the German market, thereby contributing to the healthcare sector's diversity and accessibility.

2Distribution Network

Glenmark Pharmaceuticals S.r.o. operates a distribution network within Germany, focusing on the importation and distribution of pharmaceutical products sourced from India. While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic positioning in Germany enables efficient distribution across the country. Glenmark Pharmaceuticals Limited's European operations, including those in Germany, are supported by a network of subsidiaries and partners, facilitating the seamless movement of goods and ensuring compliance with regional regulatory standards.

3Industry Role

In Germany's pharmaceutical supply chain, Glenmark Pharmaceuticals S.r.o. serves as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from India, the company ensures the availability of Glenmark's products in the German market. This role is crucial in maintaining a diverse and competitive pharmaceutical landscape, providing healthcare professionals and patients with access to a broader range of therapeutic options.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Glenmark Pharmaceuticals S.r.o.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Glenmark Pharmaceuticals S.r.o. demonstrates a high level of sourcing concentration, with 94% of its imports from India originating from its parent company, Glenmark Pharmaceuticals Limited. This significant dependency indicates a strategic choice to maintain consistency in product quality and supply chain management. The remaining 6% of imports are sourced from six other Indian suppliers, suggesting a diversified yet controlled approach to procurement. The stability of this sourcing relationship is evidenced by the substantial number of shipments—1,661 from Glenmark Pharmaceuticals Limited and 49 from Macleods Pharmaceuticals Limited—indicating a robust and reliable supply chain.

2Supply Chain Resilience

Glenmark Pharmaceuticals S.r.o.'s supply chain resilience is bolstered by its primary sourcing from Glenmark Pharmaceuticals Limited, a well-established entity with a global presence. The inclusion of additional suppliers, such as Macleods Pharmaceuticals Limited and Unison Pharmaceuticals Private Limited, introduces a level of diversification, mitigating potential risks associated with sole-source dependency. However, the limited number of suppliers may expose the company to supply chain disruptions if any of these suppliers face operational challenges. The company's focus on finished pharmaceutical formulations ensures compliance with international quality standards, enhancing the overall resilience of its supply chain.

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the primary regulatory authority overseeing the pharmaceutical sector. The Medicines Act (Arzneimittelgesetz) serves as the key legislation governing pharmaceutical imports, ensuring that all imported medications meet the country's safety, efficacy, and quality standards. For Indian generics to be marketed in Germany, they must undergo a marketing authorization process, which includes demonstrating bioequivalence to the reference product and compliance with Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing in Germany requires that pharmaceutical products possess a valid marketing authorization issued by BfArM. Indian exporters must ensure that their manufacturing facilities are certified under EU GMP or WHO GMP standards, as these are recognized by German authorities. Additionally, obtaining wholesale distribution authorization is essential for the legal distribution of pharmaceutical products within Germany.

3Quality & Labeling

Glenmark Pharmaceuticals S.r.o. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Glenmark Pharmaceuticals S.r.o. focuses on importing pharmaceutical formulations in the therapeutic areas of antimalarial and antiparasitic agents, as well as antivirals. The substantial import value of atovaquone and efavirenz indicates a strategic emphasis on these categories, likely driven by market demand for effective treatments in these areas. The company's portfolio concentration, with the top five products accounting for 100% of imports, suggests a targeted approach to meet specific therapeutic needs within the German market.

2Sourcing Profile

Glenmark Pharmaceuticals S.r.o. primarily sources generic drug formulations from India, focusing on finished pharmaceutical products rather than active pharmaceutical ingredients (APIs). This strategy aligns with the company's objective to provide ready-to-market solutions that meet the therapeutic needs of the German population. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable partner for Glenmark Pharmaceuticals S.r.o.'s procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Glenmark Pharmaceuticals S.r.o.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Glenmark Pharmaceuticals S.r.o., especially if they can offer complementary products or specialized formulations that align with the company's existing portfolio. Identifying gaps in Glenmark Pharmaceuticals S.r.o.'s current sourcing, such as unmet therapeutic needs or emerging market trends, can provide a strategic entry point for new suppliers.

2Requirements & Qualifications

Indian exporters aiming to supply Glenmark Pharmaceuticals S.r.o. and the German market must ensure that their manufacturing facilities are certified under EU GMP or WHO GMP standards. Obtaining marketing authorization from BfArM is essential, which involves demonstrating bioequivalence to reference products and compliance with German regulatory requirements. Additionally, products must meet labeling and serialization mandates to ensure market acceptance.

3How to Approach

To build a relationship with Glenmark Pharmaceuticals S.r.o., Indian exporters should initiate discussions highlighting their product offerings, quality standards, and compliance with regulatory requirements. Participating in relevant tenders and industry events can enhance visibility and credibility. Developing a clear regulatory filing strategy, including timelines for obtaining necessary certifications and approvals, is crucial for successful market entry.

Frequently Asked Questions — Glenmark Pharmaceuticals S.r.o.

What products does Glenmark Pharmaceuticals S.r.o. import from India?

Glenmark Pharmaceuticals S.r.o. imports 2 pharmaceutical products across 2 categories. Top imports: Atovaquone ($750.0K), Efavirenz ($390.3K).

Who supplies pharmaceuticals to Glenmark Pharmaceuticals S.r.o. from India?

Glenmark Pharmaceuticals S.r.o. sources from 7 verified Indian suppliers. The primary supplier is Glenmark Pharmaceuticals Limited (94.0% of imports, $38.0M).

What is Glenmark Pharmaceuticals S.r.o.'s total pharmaceutical import value?

Glenmark Pharmaceuticals S.r.o.'s total pharmaceutical import value from India is $1.1M, based on 33 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Glenmark Pharmaceuticals S.r.o. focus on?

Glenmark Pharmaceuticals S.r.o. imports across 2 categories. The largest: Antimalarial & Antiparasitic (65.8%), Antivirals (34.2%).

Get Full Glenmark Pharmaceuticals S.r.o. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.